Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27047722 | 1.00 | HCAR2 (0.52) | HCAR2CYP11B2CYP11B1MYCABL1 | |
| SCHEMBL14395820 | 0.84 | HCAR2 (0.52) | HCAR2CYP11B2CYP11B1MYCABL1 | |
| SCHEMBL2722765 | 0.75 | HCAR2 (0.67) | HCAR2CYP11B2CYP11B1MYCKDM4E | |
| SCHEMBL15047255 | 0.75 | HCAR2 (0.55) | HCAR2CYP11B2CYP11B1MYCABL1 | |
| SCHEMBL25640332 | 0.74 | HCAR2 (0.42) | HCAR2MYCSCN10A | |
| SCHEMBL27044477 | 0.74 | HCAR2 (0.42) | HCAR2MYCSCN10A | |
| SCHEMBL25643185 | 0.73 | HCAR2 (0.41) | HCAR2 | |
| SCHEMBL25642601 | 0.72 | HCAR2 (0.42) | HCAR2 | |
| SCHEMBL25455385 | 0.71 | HCAR2 (0.39) | HCAR2ABL1 | |
| SCHEMBL19249759 | 0.71 | HCAR2 (0.50) | HCAR2MYCMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HCAR2 675/4885CYP11B2 1067/4885CYP11B1 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.